NCT04388904View on ClinicalTrials.gov

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
HIV-1-infection
Interventions
DRUG

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)

Participants will receive Symtuza®. An oral tablet containing Darunavir 800 mg /Cobicistat 150 mg /Emtricitabine 200 mg /Tenofovir Alafenamide 10 mg FDC, once daily within 24 hours of the screening/ baseline visit.

Trial Locations (1)

77098

The Crofoot Research Center, Inc., Houston

All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

The Crofoot Research Center, Inc.

INDUSTRY

NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) | Biotech Hunter | Biotech Hunter